Since the incident, the FDA has been reviewing safety and production procedures at the facility. But despite the US government handing over control to J&J, attempts to re-start production have been in limbo, and according to the NYT, another 60MM doses produced at the facility didn't meet the agency's safety standards.
LOL 喵同學
: Of the ruined doses, 10MM will be sold in the US, and abroad with a special warning label that regulators can use for drugs that are in short supply. The warning will read that "regulators cannot guarantee that Emergent BioSolutions, the company that operates the plant, followed good manufacturing practices."
看來 J&J 的律師團應該是已經開始在準備要告倒 Emergent 了可以給台灣